{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T04:09:22Z","timestamp":1773461362219,"version":"3.50.1"},"reference-count":49,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJPR23R7"],"award-info":[{"award-number":["JPMJPR23R7"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["21HA2018"],"award-info":[{"award-number":["21HA2018"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,6,5]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>During the COVID-19 pandemic, many clinical trials were conducted to identify effective COVID-19 therapeutics. However, while a large amount of resources was invested and significant numbers of patients participated, this did not necessarily have an impact on clinical practice. To face these issues, initiatives such as the 100 Days Mission have been set out globally. Yet, limited data exist on the context surrounding the implementation of clinical trials at a national level during a health emergency. The study explored experiences and perceptions of principal investigators in conducting clinical trials for COVID-19 therapeutics in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A qualitative study was conducted using semistructured interviews. The obtained data were inductively analysed using thematic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting and participants<\/jats:title>\n                    <jats:p>We interviewed 15 principal investigators between September and November 2022 who conducted investigator-initiated clinical trials on the development of COVID-19 therapeutics in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three themes were generated:\n                      <jats:bold>structural barriers<\/jats:bold>\n                      ,\n                      <jats:bold>fragmented efforts<\/jats:bold>\n                      and\n                      <jats:bold>limited evidence generation<\/jats:bold>\n                      .\n                      <jats:bold>Structural barriers<\/jats:bold>\n                      and\n                      <jats:bold>fragmented efforts<\/jats:bold>\n                      comprised four subthemes: individual, institutional, interinstitutional and policy\/regulatory levels.\n                      <jats:bold>Structural barriers<\/jats:bold>\n                      at all levels included (1) limitations of individual capabilities, (2) the double burden of clinical practice and research, (3) inefficient interinstitutional collaboration and (4) regulatory frameworks and available resources that interrupt stakeholders\u2019 actions, leading to\n                      <jats:bold>limited evidence generation<\/jats:bold>\n                      despite the\n                      <jats:bold>fragmented efforts<\/jats:bold>\n                      of principal investigators and other stakeholders.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study illustrated that the efforts of Japanese principal investigators did not necessarily pay off in identifying therapeutics. A strategic and systematic approach for an improved national clinical trial ecosystem must be sought during the interpandemic period to overcome structural barriers in harmonisation with the global stakeholders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-097611","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:51:34Z","timestamp":1750751494000},"page":"e097611","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Principal investigators\u2019 experience of COVID-19 therapeutic clinical trials in Japan: a qualitative study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8459-1498","authenticated-orcid":false,"given":"Satoko","family":"Horii","sequence":"first","affiliation":[{"name":"School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan"},{"name":"Graduate School of Health and Welfare Management, Bunkyo Gakuin University, Bunkyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6477-8204","authenticated-orcid":false,"given":"Hiroki","family":"Saito","sequence":"additional","affiliation":[{"name":"Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Emergency and Critical Care Medicine, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3031-6117","authenticated-orcid":false,"given":"Taro","family":"Shibata","sequence":"additional","affiliation":[{"name":"Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Chuo-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-9275","authenticated-orcid":false,"given":"Miwa","family":"Sonoda","sequence":"additional","affiliation":[{"name":"Department of International Trials, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5244-3458","authenticated-orcid":false,"given":"Tatsuo","family":"Iiyama","sequence":"additional","affiliation":[{"name":"Department of International Trials, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4679-3862","authenticated-orcid":false,"given":"Kazuaki","family":"Jindai","sequence":"additional","affiliation":[{"name":"Department of Virology, Tohoku University, Sendai, Miyagi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"2025121223510871000_15.6.e097611.1","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.7326\/M21-1269","article-title":"Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics","volume":"174","author":"LaVange","year":"2021","journal-title":"Ann Intern Med"},{"key":"2025121223510871000_15.6.e097611.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m2670","article-title":"Covid-19: The inside story of the RECOVERY trial","volume":"370","author":"Wise","year":"2020","journal-title":"BMJ"},{"key":"2025121223510871000_15.6.e097611.3","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2214-109X(20)30542-8","article-title":"How COVID-19 has fundamentally changed clinical research in global health","volume":"9","author":"Park","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2025121223510871000_15.6.e097611.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00503-1"},{"key":"2025121223510871000_15.6.e097611.5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.12688\/wellcomeopenres.17284.1","article-title":"The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions","volume":"7","author":"McLean","year":"2022","journal-title":"Wellcome Open Res"},{"key":"2025121223510871000_15.6.e097611.6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.35772\/ghm.2020.01106","article-title":"Investigator initiated clinical trial of remdesivir for the treatment of COVID-19 in Japan","volume":"3","author":"Saito","year":"2021","journal-title":"Glob Health Med"},{"key":"2025121223510871000_15.6.e097611.7","unstructured":"Saito H . Issues in sepsis practice guidelines from the perspective of infectious disease treatment \u201cclinical research and data utilization\u201d in Japanese. The 97th Annual Meeting of the Japanese Society of Infectious Diseases; 2023"},{"key":"2025121223510871000_15.6.e097611.8","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01897-20","article-title":"A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19","volume":"64","author":"Doi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025121223510871000_15.6.e097611.9","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00517-4"},{"key":"2025121223510871000_15.6.e097611.10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.12688\/f1000research.129241.1","article-title":"Global landscape of randomized controlled trials responding to the COVID-19 pandemic: a literature review protocol","volume":"12","author":"Inada","year":"2023","journal-title":"F1000Res"},{"key":"2025121223510871000_15.6.e097611.11","unstructured":"100 days mission to respond to future pandemic threats. A report to the G7 by the pandemic preparedness partnership 2021. Available: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/992762\/100_Days_Mission_to_respond_to_future_pandemic_threats__3_.pdf [Accessed 01 Jul 2024]."},{"key":"2025121223510871000_15.6.e097611.12","unstructured":"The International Pandemic Preparedness Secretariat (IPPS) . 100 days mission implementation report \u20142023. 2024. Available: https:\/\/d7npznmd5zvwd.cloudfront.net\/prod\/uploads\/2024\/01\/240226_100DM-3rd-Implementation-Report.pdf [Accessed 01 Jul 2024]."},{"key":"2025121223510871000_15.6.e097611.13","unstructured":"75th World Health Assembly . Strengthening clinical trials to provide high-quality evidence on health interventions and to improve research quality and coordination. 2022. Available: https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA75\/A75_R8-en.pdf [Accessed 20 Aug 2024]."},{"key":"2025121223510871000_15.6.e097611.14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(23)02798-8","article-title":"The future of the global clinical trial ecosystem: a vision from the first WHO Global Clinical Trials Forum","volume":"403","author":"Moorthy","year":"2024","journal-title":"Lancet"},{"key":"2025121223510871000_15.6.e097611.15","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"2025121223510871000_15.6.e097611.16","unstructured":"Cresswell JW . Research design: qualitative, quantitative, and mixed methods. Approaches: SAGE Publications, 2014."},{"key":"2025121223510871000_15.6.e097611.17","unstructured":"Enhancing the QUAlity and Transparency Of health Research . Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Available: https:\/\/www.equator-network.org\/reporting-guidelines\/coreq\/ [Accessed 01 Jul 2024]."},{"key":"2025121223510871000_15.6.e097611.18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jjco\/hyaa028","article-title":"Regulatory changes after the enforcement of the new Clinical Trials Act in Japan","volume":"50","author":"Nakamura","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"2025121223510871000_15.6.e097611.19","unstructured":"Japan Registry of Clinical Trials (jRCT). Available: https:\/\/jrct.niph.go.jp [Accessed 25 Jul 2025]."},{"key":"2025121223510871000_15.6.e097611.20","unstructured":"International clinical trials registry platform. Data providers. Available: https:\/\/www.who.int\/clinical-trials-registry-platform\/network\/data-providers [Accessed 22 Mar 2025]."},{"key":"2025121223510871000_15.6.e097611.21","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"2025121223510871000_15.6.e097611.22","doi-asserted-by":"crossref","first-page":"104901","DOI":"10.1016\/j.nedt.2021.104901","article-title":"Nurses\u2019 perception of individual and organizational changes caused by a novel clinical training system for new graduate nurses: A qualitative research using photovoice","volume":"102","author":"Horii","year":"2021","journal-title":"Nurse Educ Today"},{"key":"2025121223510871000_15.6.e097611.23","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1177\/10497323231201026","article-title":"Patient Admission and Mechanical Ventilator Allocation Decision-Making Processes by Frontline Medical Professionals in a Japanese ICU During the COVID-19 Pandemic: A Qualitative Study","volume":"33","author":"Ishizaki","year":"2023","journal-title":"Qual Health Res"},{"key":"2025121223510871000_15.6.e097611.24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/cts.12942","article-title":"Performance Index for Types of Clinical Research Support Service Providers for Academic Research Organizations in Japan: A Cross-Sectional Survey","volume":"14","author":"Ueda","year":"2021","journal-title":"Clin Transl Sci"},{"key":"2025121223510871000_15.6.e097611.25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.35772\/ghm.2023.01023","article-title":"An overview of the reclassification of COVID-19 of the Infectious Diseases Control Law in Japan","volume":"5","author":"Kitahara","year":"2023","journal-title":"Glob Health Med"},{"key":"2025121223510871000_15.6.e097611.26","unstructured":"OECD . OECD reviews of public health: Japan: a healthier tomorrow. 2019. Available: https:\/\/www.oecd-ilibrary.org\/social-issues-migration-health\/oecd-reviews-of-public-health-japan_9789264311602-en [Accessed 05 Jan 2024]."},{"key":"2025121223510871000_15.6.e097611.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003616","article-title":"Understanding the investigators: a qualitative study investigating the barriers and enablers to the implementation of local investigator-initiated clinical trials in Ethiopia","volume":"3","author":"Franzen","year":"2013","journal-title":"BMJ Open"},{"key":"2025121223510871000_15.6.e097611.28","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-020-04893-z","article-title":"An investigation into the factors affecting investigator-initiated trial start-up in Ireland","volume":"21","author":"Leddy","year":"2020","journal-title":"Trials"},{"key":"2025121223510871000_15.6.e097611.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2107331"},{"key":"2025121223510871000_15.6.e097611.30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.11847","article-title":"Practices and Attitudes of Swiss Stakeholders Regarding Investigator-Initiated Clinical Trial Funding Acquisition and Cost Management","volume":"4","author":"McLennan","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025121223510871000_15.6.e097611.31","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2022.100939","article-title":"Barriers for cancer clinical trial enrollment: A qualitative study of the perspectives of healthcare providers","volume":"28","author":"Kumar","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"key":"2025121223510871000_15.6.e097611.32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2807\/1560-7917.ES.2015.20.44.30056","article-title":"Public health challenges and legacies of Japan\u2019s response to the Ebola virus disease outbreak in West Africa 2014 to 2015","volume":"20","author":"Saito","year":"2015","journal-title":"Euro Surveill"},{"key":"2025121223510871000_15.6.e097611.33","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.3191","article-title":"Strategies for Expediting Clinical Trials in the Next Public Health Emergency","volume":"4","author":"Titanji","year":"2023","journal-title":"JAMA Health Forum"},{"key":"2025121223510871000_15.6.e097611.34","unstructured":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Board on Global Health; Committee on Clinical Trials During the 2014-2015 Ebola Outbreak . Integrating clinical research into epidemic response: the Ebola experience. Washington, DC: National Academies Press (US), 2017."},{"key":"2025121223510871000_15.6.e097611.35","unstructured":"National Institute of Infectious Diseases . Infectious disease surveillance system in Japan. 2018. Available: https:\/\/www.niid.go.jp\/niid\/images\/epi\/nesid\/nesid_en.pdf [Accessed 20 Mar 2025]."},{"key":"2025121223510871000_15.6.e097611.36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/hs.2024.0044","article-title":"Hospital Preparedness for Conducting Clinical Research During a Pandemic: A Nationwide Survey Among Designated Medical Institutions for Infectious Diseases in Japan","volume":"23","author":"Jindai","year":"2025","journal-title":"Health Secur"},{"key":"2025121223510871000_15.6.e097611.37","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/cid\/ciad648","article-title":"When Someone Should Do Something About This: How a Cryptococcal Clinical Trialist Became Involved With the COVID-19 Pandemic","volume":"78","author":"Boulware","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025121223510871000_15.6.e097611.38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.35772\/ghm.2024.01082","article-title":"How to build a better clinical trial ecosystem for future infectious disease emergencies in Japan: Findings from a narrative review and stakeholder meetings","volume":"7","author":"Saito","year":"2025","journal-title":"Glob Health Med"},{"key":"2025121223510871000_15.6.e097611.39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.26892","article-title":"Funding Sources of Therapeutic and Vaccine Clinical Trials for COVID-19 vs Non-COVID-19 Indications, 2020-2021","volume":"5","author":"Angelis","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025121223510871000_15.6.e097611.40","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00705-2"},{"key":"2025121223510871000_15.6.e097611.41","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-020-03078-z","article-title":"Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series","volume":"24","author":"Doi","year":"2020","journal-title":"Crit Care"},{"key":"2025121223510871000_15.6.e097611.42","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.2169\/internalmedicine.9691-22","article-title":"The Assessment of the Efficacy and Safety of Favipiravir for Patients with SARS-CoV-2 Infection: A Multicenter Non-randomized, Uncontrolled Single-arm Prospective Study","volume":"61","author":"Yanagisawa","year":"2022","journal-title":"Intern Med"},{"key":"2025121223510871000_15.6.e097611.43","unstructured":"Favipiravir observational study, 4th interim report. As of July 1st, 2021. 2021. Available: https:\/\/www.kansensho.or.jp\/uploads\/files\/topics\/2019ncov\/covid19_favip_210701.pdf [Accessed 01 Jul 2024]."},{"key":"2025121223510871000_15.6.e097611.44","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1473-3099(23)00193-7","article-title":"International platform trials: as diseases cross borders, so should trials","volume":"23","author":"Saito","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025121223510871000_15.6.e097611.45","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(23)00690-6","article-title":"Promote global solidarity to advance health-system resilience: proposals for the G7 meetings in Japan","volume":"401","year":"2023","journal-title":"Lancet"},{"key":"2025121223510871000_15.6.e097611.46","doi-asserted-by":"publisher","DOI":"10.4103\/picr.PICR_77_20"},{"key":"2025121223510871000_15.6.e097611.47","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.12867"},{"key":"2025121223510871000_15.6.e097611.48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.234"},{"key":"2025121223510871000_15.6.e097611.49","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/hex.12634","article-title":"Talking to the people that really matter about their participation in pandemic clinical research: A qualitative study in four European countries","volume":"21","author":"Gobat","year":"2018","journal-title":"Health Expect"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-097611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:51:19Z","timestamp":1765612279000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-097611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,7,10]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bmjopen-2024-097611"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-097611","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}